Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.7 (plasmin)
 9,023 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The safety and efficacy of plasmin-treated gamma globulin (PG-GG), an intravenous preparation with low anticomplementary activity, was assessed as an antibody replacement therapy in 14 patients with hypogammaglobulinemia. Seven were studied in 2 treatment periods of 6 and 15 mo on PT-GG with an intervening control period of intramuscular gamma globulin (IM-ISG). Frequency of infusions ranged from 2 to 4 wk to maintain a serum IgG concentration of less than 2.5 mg/ml. Three patients with severe chronic pulmonary disease were removed from the study because of lack of clinical improvement and were placed on single-donor plasma. The remaining 11 patients had a decrease in the number of hospitalizations or severe infections. Five patients had one or more systemic reactions (21/240 infusions). Symptoms abated rapidly with temporary interruption of the infusion. From these results, we conclude that PT-GG represents a relatively safe, efficacious mode of replacement therapy which has had uniformly high acceptance in patients with hypogammaglobulinemia.
 ...
PMID:Intravenous gamma globulin in the management of patients with hypogammaglobulinemia. 7 67

The need for quantitative or qualitative immunoglobulin replacement therapy in patients with hypogammaglobulinaemia or in immuno-compromised subjects has greatly encouraged the development of preparations suitable for intravenous use. A major requirement in plasma fractionation is that ready-to-use preparations must be free from contamination by immunoglobulin aggregates likely to produce harmful reactions. To avoid this, three methods are available:--splitting-up with enzymes (pepsin or plasmin) which separate the Fc and Fab fragments, thereby damaging the molecule and definitely preventing the formation of IgG aggregates;--treatment of the preparation with chemical compounds altering the primary structure of the molecule that mediates spontaneous aggregation;--adjunction of special agents (e.g. polyethyleneglycol) or treatment at low pH, which eliminates IgG aggregates and prevents them from forming anew. The properties of immunoglobulins prepared by these three methods are discussed on the basis of two criteria: clinical tolerability and therapeutic effectiveness, including antigen neutralization, sustained normal half-life and full ability to interact with humoral and cellular receptors.
 ...
PMID:[Evaluation criteria for intravenous immunoglobulin G preparations]. 622